AbbVie successor to Humira in psoriasis gains FDA approval

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Apr 23, 2019 at 11:02 PM.

  1. #1 cafead, Apr 23, 2019 at 11:02 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,039
    Likes Received:
    3
    via With Humira set to face increasing biosimilar competition internationally this year, AbbVie notched its first U.S. approval for a successor to the blockbuster, Skyrizi (risankizumab-rzaa), late Tuesday. FDA approved the IL-23 inhibitor to treat plaque psoriasis, one of at least 10 indications on Humira adalimumab’s label.

    article source
     
    Quote

Reply to Thread